Most of us treat the annual full-body checkup as a reassuring ritual: a few vials of blood, a number for cholesterol and blood sugar, and a doctor who tells us whether things look fine. For most people, most of the time, that's exactly the right amount of testing. It's not that the checkup is doing something wrong. It's that it was built to answer a specific, narrower question than the one many people assume it's answering.

What the standard checkup is actually designed to do

A typical annual panel, a complete blood count, a basic metabolic panel, liver and kidney function, and a standard lipid panel (total cholesterol, LDL, HDL, triglycerides), exists to catch disease once it's crossed a clinically defined threshold, and to monitor known risk factors like diabetes or hypertension once they're established. These are well-validated, widely used tools, and for population-level screening, they work. The lipid panel specifically was developed decades ago as a practical, affordable way to flag large numbers of people at elevated cardiovascular risk, and it still does that job reasonably well for most people.

What it isn't designed to do is catch the earlier, subtler signals that sometimes precede a diagnosis by years. That's a different job, and it generally requires different, more specific markers, not a replacement for the basic panel, but an addition to it for people who have a reason to look closer.

The cardiovascular example: when a "normal" cholesterol result doesn't tell the whole story

Cardiology research over the past two decades has identified a genuine gap here. LDL cholesterol measures the amount of cholesterol carried by LDL particles, but it doesn't directly count how many of those particles there are. Two people can have an identical LDL-cholesterol number while carrying very different numbers of actual atherogenic particles, a phenomenon researchers call "discordance." A 2019 narrative review in JAMA Cardiology laid out the physiological case for why apolipoprotein B (ApoB), which directly reflects particle count, more accurately tracks cardiovascular risk than LDL-C in these discordant cases, a conclusion a 2022 review in the Journal of the American Heart Association revisited and reinforced. The European Society of Cardiology and European Atherosclerosis Society's own 2019 guidelines recognised ApoB as a more accurate risk marker than LDL-C for this reason.

Lipoprotein(a), or Lp(a), is another example: an inherited, independent cardiovascular risk factor present in roughly one in five people, that simply isn't part of a standard lipid panel at all. Someone with a family history of early heart disease and an entirely unremarkable standard cholesterol result can still be carrying this risk factor without ever knowing it, because it was never tested.

None of this means the standard lipid panel is wrong or that the doctors who rely on it are missing something they should have caught. It means these additional markers answer a more specific question, usually relevant to a smaller group of people: those with a family history of early cardiovascular disease, a lipid result that doesn't match their overall risk picture, or a reason to want a more granular baseline.

The same pattern shows up elsewhere

The cardiovascular example is the best-studied case, but the underlying pattern repeats across other areas of preventive health: a handful of markers (inflammatory, metabolic, hormonal) that sit outside a standard panel but can add real context for the right person, at the right time, interpreted by a doctor rather than read in isolation. This is part of why preventive health programs in a number of countries have started offering broader biomarker panels alongside, not instead of, routine care. The growth of advanced blood testing in Australia, for instance, reflects this same shift toward giving people and their doctors a more complete baseline to work from.

What this actually means for you

This isn't a case for skipping your regular checkup or routine doctor visits, both remain the foundation of good preventive care, and a qualified physician is still the right person to interpret any result, standard or expanded. What it does mean is that if you have a specific reason for concern, a strong family history of heart disease, a cholesterol result that doesn't match the rest of your risk profile, or simply a wish for a more detailed baseline, it's worth asking your doctor whether additional, more targeted markers make sense for you. The right test is always the one that answers the question you actually have, and for most people, that's still the one your doctor already orders.